Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.70 |
| ▸ | RAB9A | P51151 | 5/20 | 0.70 |
| ▸ | METAP2 | P50579 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 6/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | GAA | P10253 | 2/20 | 0.65 |
| ▸ | PNLIP | P16233 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.61 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.61 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.61 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.61 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.61 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30235899 | 1.00 | NPC1 (0.70) | NPC1RAB9AMETAP2MEN1KMT2A | |
| SCHEMBL17744848 | 0.87 | PTGS1 (0.75) | NPC1RAB9AMEN1KMT2ALMNA | |
| SCHEMBL5674964 | 0.84 | PNLIP (0.70) | MEN1KMT2ALMNAALDH1A1PNLIP | |
| SCHEMBL30726106 | 0.84 | NPC1 (0.71) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL9208778 | 0.84 | NPC1 (0.71) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL5798244 | 0.84 | RAB9A (0.72) | NPC1RAB9AMEN1KMT2ALMNA | |
| SCHEMBL2568848 | 0.83 | SMN1; SMN2 (0.66) | NPC1RAB9AMEN1KMT2ALMNA | |
| SCHEMBL3949532 | 0.83 | KMT2A (0.78) | NPC1RAB9AMETAP2MEN1KMT2A | |
| SCHEMBL5080078 | 0.83 | PNLIP (0.91) | NPC1RAB9AMETAP2MEN1KMT2A | |
| SCHEMBL12189549 | 0.83 | NPC1 (0.72) | NPC1RAB9AMETAP2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118184588-A | N-aryl/alkyl quinazolinone compound and synthesis method thereof | 陕西科技大学 | 2024-06-14 | — | — | CN | claimed |
| CN-104829543-B | A kind of 2 (4 oxoalkyl group) quianzolinones and its synthetic method | 三峡大学 | 2017-08-25 | — | — | CN | claimed |
| CN-118184588-A | N-aryl/alkyl quinazolinone compound and synthesis method thereof | 陕西科技大学 | 2024-06-14 | — | — | CN | disclosed |
| CN-117510415-A | Synthesis method of quinazolinone compound | 中国人民解放军军事科学院防化研究院 | 2024-02-06 | — | — | CN | disclosed |
| CN-111646908-B | Method for preparing aromatic amine compound | 宜昌尚诺德生物医药科技有限公司 | 2023-03-10 | — | — | CN | disclosed |
| CN-111732493-B | Synthesis process of arylamine compound | 宜昌尚诺德生物医药科技有限公司 | 2023-01-24 | — | — | CN | disclosed |
| CN-111732493-A | Synthesis process of arylamine compound | 宜昌尚诺德生物医药科技有限公司 | 2020-10-02 | — | — | CN | disclosed |
| CN-111646908-A | Method for preparing aromatic amine compound | 宜昌尚诺德生物医药科技有限公司 | 2020-09-11 | — | — | CN | disclosed |
| CN-106800493-B | Method for reducing aromatic nitro group into aromatic amine | 宜昌尚诺德生物医药科技有限公司 | 2020-06-30 | — | — | CN | disclosed |
| EP-2951179-B1 | SPIRO-QUINAZOLINONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND CONDITIONS | MERCK PATENT GMBH (DE) | 2020-03-11 | — | — | EP | disclosed |
| CN-104829543-B | A kind of 2 (4 oxoalkyl group) quianzolinones and its synthetic method | 三峡大学 | 2017-08-25 | — | — | CN | disclosed |
| US-20030195223-A1 | An anticoagulant, blood inhibitor of factor Xa, a N1-amidinebenzoyl- N2-benzoyl-1,2-benzenediamine derivatives; chemical intermediates | BEIGHT DOUGLAS WADE (US) | 2003-10-16 | — | — | US | disclosed |
| US-6605626-B2 | Benzamide inhibitors of factor Xa | ELI LILLY AND COMPANY | 2003-08-12 | — | — | US | disclosed |
| US-20020120007-A1 | Benzamide inhibitors of factor Xa | BEIGHT DOUGLAS WADE (US) | 2002-08-29 | — | — | US | disclosed |
| US-6417200-B1 | BLOOD COAGULATION FACTOR XA IN MAMMALS | ELI LILLY AND COMPANY | 2002-07-09 | — | — | US | disclosed |
| US-6313122-B1 | AS INHIBITORS OF FACTOR XA AND ARE USED AS ANTICOAGULANTS IN MAMMALS | ELI LILLY AND COMPANY | 2001-11-06 | — | — | US | disclosed |
| EP-1014962-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 2000-07-05 | — | — | EP | disclosed |
| EP-1007037-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 2000-06-14 | — | — | EP | disclosed |
| WO-1999000127-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1999-01-07 | — | — | WO | disclosed |
| WO-1999000121-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1999-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195223-A1 | An anticoagulant, blood inhibitor of factor Xa, a N1-amidinebenzoyl- N2-benzoyl-1,2-benzenediamine derivatives; chemical intermediates | F12, F11, F2 | NPC1 1837/4885RAB9A 2402/4885METAP2 1428/4885 |
| US-20020120007-A1 | Benzamide inhibitors of factor Xa | TFPI, F11, F12 | NPC1 1618/4885RAB9A 2658/4885METAP2 1246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.